Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
about
Maraviroc: a review of its use in HIV infection and beyondCCR5 antagonism in HIV infection: current concepts and future opportunitiesEnv-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors
P2860
Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Synergistic inhibition of R5 H ...... s for treatment and prevention
@en
Synergistic inhibition of R5 H ...... for treatment and prevention.
@nl
type
label
Synergistic inhibition of R5 H ...... s for treatment and prevention
@en
Synergistic inhibition of R5 H ...... for treatment and prevention.
@nl
prefLabel
Synergistic inhibition of R5 H ...... s for treatment and prevention
@en
Synergistic inhibition of R5 H ...... for treatment and prevention.
@nl
P2093
P2860
P1433
P1476
Synergistic inhibition of R5 H ...... s for treatment and prevention
@en
P2093
Alonso Heredia
Anthony DeVico
James S Foulke
Marvin Reitz
Olga Latinovic
Ranajit Pal
Robert R Redfield
P2860
P304
P356
10.1097/QAD.0B013E3283471EDB
P407
P577
2011-06-01T00:00:00Z